FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| OMB APPROVAL | | | | | | | |
|--------------------------|-----------|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | |
| Estimated average burden | | | | | | | |
| hours per response: | 0.5 | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* Almon Einat Brill | | | | | Pro | 2. Issuer Name and Ticker or Trading Symbol Protalix BioTherapeutics, Inc. [PLX] | | | | | | | | | ationship k all applic Directo | , | | son(s) to Is | |
|--|--|--|-----------------|---|---------------------------------|--|-----------|---|------------------|---|--------------------|--|-----------------------------------|--------------------------------------|---|---|---------------|--|----------------------------|
| (Last) | (Fi | rst) (| | 3. Date of Earliest Transaction (Month/Day/Year) 05/02/2012 | | | | | | | | | | Officer (give title below) | | Other (s below) | specify | | |
| C/O PRO | | | | | | | | | | | | SVP, Product Development | | | | | | | |
| 2 SNUN | 4. If A | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | | | 6. Individual or Joint/Group Filing (Check Applicable Line) | | | | | | | |
| (Street) | | | | | | | | | | | | | X | X Form filed by One Reporting Person | | | | | |
| CARMII |) | | | | | | | | | | | | led by Mor | e than | One Repo | orting | | | |
| (City) | (St | tate) (| Zip) | | | | | | | | | | | | | | | | |
| | Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | | | | | | | |
| 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day) | | | | //Year) i | Execu f any | a. Deemed ecution Date, any onth/Day/Year) | | 3. Transaction Code (Instr. 8) | | 4. Securities Acquired (ADisposed Of (D) (Instr. 3.5) | | | 4 and Securit Benefic Owned | | ies ially | 6. Ownership Form: Direct (D) or Indirect (I) | | 7. Nature of Indirect Beneficial Ownership | |
| | | | | | | Code | v | Amount | (A) (D) | or Pric | e:e | Following Reporte Transac (Instr. 3 | d tion(s) | | . 4) | (Instr. 4) | | | |
| Common | Stock | 05/02/2 | 012 | ! | | M | | 116,84 | 8 A | \$0 | .972 | 116 | 116,848 | | | By trust ⁽²⁾ | | | |
| Common Stock 05/0 | | | | | 012 | | | | M | | 50,000 |) A | \$2 | .65 | 166,848 | | | | By trust ⁽²⁾ |
| Common Stock 05/02/20 | | | | | 012 | 12 | | | S | | 166,848 | (1) D | \$7 | '.13 | 0 | | | | By trust ⁽²⁾ |
| | | | Tal | ble II - Der (e.q | | | | | | | osed of, c | | | Ow | ned | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | Execu if any | eemed tion Date, h/Day/Year) | 4. Transac Code (Ir 8) | 5. Number tion of | | | | Exerc | isable and | 7. Title and Amount of Securities Underlying Derivative Sec (Instr. 3 and 4 | | rity | 3. Price of Derivative Security Instr. 5) | 9. Numbe derivative Securities Beneficial Owned Following Reported Transacti (Instr. 4) | e s lly | 10. Ownership Form: Direct (D) or Indirec (I) (Instr. 4) | Beneficial Ownership |
| | | | | | Code | v | V (A) (D) | | Date Exercisa | able | Expiration Date | An or Nu of Title | | er | | | | | |
| Stock Options (Right to Buy) | \$0.972 | 05/02/2012 | | | M | | | 116,848 | (3) | | 08/13/2016 | Common Stock | 116,8 | 348 | \$0 | 0 ⁽⁴⁾ | | D | |
| Stock Options (Right to | \$2.65 | 05/02/2012 | | | M | | | 50,000 | (3) | | 02/25/2019 | Common Stock | 50,0 | 00 | \$0 | 0 ⁽⁴⁾ | | D | |

Explanation of Responses:

- 1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- 2. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee upon the exercise of stock options must be registered in the name of a trustee.
- 3. All options are fully vested.
- 4. Does not include (i) options to purchase 311,272 shares of common stock at an exercise price equal to \$5.00 per share that expire on February 7, 2018 and (ii) options to purchase 130,000 shares of common stock at an exercise price equal to \$6.90 per share that expire on February 25, 2020.

/s/ Yossi Maimon, POA 05/04/2012

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

 $^{^{\}star}$ If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | |
|--|--|
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |